Political solutions . . . A large number of drugs "difficult to escape" collection of lost trust pharmaceutical enterprises inch by inch difficult to walk!

Wen/Linan "the wind and the wind, the grass and the wood are all soldiers."
the second half of 2020, it's all about it.
summer is hot, heavy rain.
july, the third batch of national harvests is still the main play.
Any wind and grass movement can cause a lot of concern in the industry, near the end of the month, the third batch of national mining documents officially issued, the relevant rules and varieties of procurement volume open, 56 varieties involving more than 100 pharmaceutical enterprises, according to the effect of the first two batches, whether the enterprise winning bid or not, directly affect the market share of varieties.
, and under the policy of health insurance balance, enterprises are expected to lose a large number of markets if they lose their bids.
billions of markets face a shuffle as a new round of harvesting opens in August.
with the normalization of belt procurement in the field of chemical drugs, the collection of biological and traditional Chinese medicines is also gradually advancing.
In the middle of this month, the Health Insurance Bureau held a symposium on the disclosure of this news, and then the network will be 500 varieties will be national, provincial, municipal collection and full coverage, and completed within 3 years, varieties involving a number of heavy biological drugs, insulin products, and all provinces in the country this year need to carry out with the volume of procurement, clinical use of large, the amount of high proportion of varieties expected to be "difficult to escape" the fate of the collection.
Under the vast volume of procurement, the list of pharmaceutical prices and the collection of unconscionable matters, including but not limited to the purchase and sale of medicine to give kickbacks or commercial bribery, abuse of market dominance, tax-related violations, improper price behavior, malicious breach of contract agreements, disrupt the centralized procurement order and so on.
, in the future, pharmaceutical companies in the event of a loss of trust, its product sales and market will be affected.
addition, this month began until the end of the year, the National Health And Health Commission will focus on medical personnel to collect kickbacks, illegal marketing of pharmaceutical companies and other acts, with gold sales model on the brink of death.
The 2020 edition of the Pharmacopoeia of the People's Republic of China was promulgated, supplies are about to be launched, crown stents first, the State Drug Administration issued "breakthrough treatment drug review work procedures" and other three documents;
.